Evaluation of Intracranial Pressure Time Dose by the New Integra CereLink ICP Monitor

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

The new Integra CereLink ICP monitor integrate the possibility of recording and displaying continuously the AUC (Pressure Time Dose, PTD) and other ICP derived variables and provide the possibility of evaluating the utility of this information at the bedside. It offers the opportunity to test in a standardized way the clinical value of the PTD computation in this setting. Therefore, this study aims to test clinically if PTD recorded continuously is associated to patients' outcome and to identify a threshold of PTD associated with the transition from good to negative outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Aged within 18 and 80 years;

• Diagnosed of an acute brain injury (ABI) for hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury;

• ICP monitoring started for clinical indication and accordingly to local policies

• ICP device connected to the Integra CereLink ICP monitor.

Locations
Other Locations
Italy
Fondazione IRCCS San Gerardo dei Tintori
RECRUITING
Monza
Contact Information
Primary
Giuseppe Citerio, Professor
giuseppe.citerio@unimib.it
+39039233
Time Frame
Start Date: 2023-11-13
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 250
Sponsors
Collaborators: Integra LifeSciences Corporation
Leads: University of Milano Bicocca

This content was sourced from clinicaltrials.gov